HER2+ Breast Cancer

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses adjuvant therapy for patients with HER2-postive breast cancer.

Haythem Y. Ali, MD, discusses adjuvant advances in HER2-postitive breast cancer and emerging agents in the field.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses the adjuvant treatment of patients with HER2-positive breast cancer.

A shorter 6-month course of adjuvant trastuzumab (Herceptin) was found to be noninferior for disease-free survival compared with the standard 12-month schedule for patients with HER2-positive early breast cancer.

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses immunotherapy in HER2-positive breast cancer.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Kelly McCann, MD, PhD, discusses the therapies available for patients with HER2-positive breast cancer and the potential benefit with additional subtyping in the field.

A panel of experts discuss the latest developments in the treatment of patients with HER2-positive breast cancer.

Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the promise of immunotherapy in the treatment of patients with HER2-positive breast cancer.